Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

In biomarkers we trust?

Nature Biotechnology volume 23, pages 297–304 (2005)Cite this article

The 'omics revolution offers plenty of decision-making tools. It's knowing how to use them that's key.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Growth of biomarker markets in millions.
Figure 2: Analyte profiling.
Figure 3: Comparative profiling.

References

  1. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).

    Article  CAS  Google Scholar 

  2. Woodcock, J. A Framework for Biomarker and Surrogate Endpoint Use in Drug Development (US Food and Drug Adminisration, Rockville, MD, 2004). http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4079S2_03_Woodcock_files/frame.htm

  3. Rubenstein, K. Post-genomic biomarkers: revolutionizing drug development and diagnostics (D&MD Publications, Westborough, MA, 2003).

    Google Scholar 

  4. Wei, C.-M. et al. Endothelin in human congestive heart failure. Circulation, 89, 1580–1586 (1994).

    Article  CAS  Google Scholar 

  5. De Meyer, G. & Shapiro, F. Biomarker development: the road to clinical utility. Current Drug Discovery 12, 23–27 (2003).

    Google Scholar 

  6. Fleming, T.R. & DeMets, D.L. Surrogate endpoints in clinical trials: are we being mislead? Ann. Intern. Med. 125, 605–613 (1996)

    Article  CAS  Google Scholar 

  7. Frank, R. & Hargreaves, R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2, 566–580 (2003).

    Article  CAS  Google Scholar 

  8. Rolan, P., Atkinson, A.J. Jr. & Lesko, L.J. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin. Pharmacol. Ther. 73, 284–291 (2003).

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Monya Baker is a science writer living in San Francisco.

    • Monya Baker
Authors
  1. Monya Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

https://doi.org/10.1038/Nat.Biotechnol.22,6-7(2004)

https://doi.org/10.1038/Nat.Biotechnol.23,3-4(2005)

Related external links

A Framework for Biomarker and Surrogate Endpoint Use in Drug Development

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baker, M. In biomarkers we trust?. Nat Biotechnol 23, 297–304 (2005). https://doi.org/10.1038/nbt0305-297

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0305-297

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing